title: [Short and long-term therapeutic effects of rapamycin-eluting stent and paclitaxel-eluting stent in treatment of coronary disease with complicated lesions].
abstract: OBJECTIVE
  To compare the short and long-term clinical outcomes of rapamycin (sirolimus)-eluting stent (DES) (CYPHER stent) and paclitaxel-DES (TAXUS stent) in treatment of coronary heart disease (CHD) patients with complicated lesions.
  
  
  METHODS
  611 CHD patients with 642 lesions, were treated with 698 CYPHER stents, and 450 sex, age, clinical data and lesion type-matched patients, with 534 lesions, were treated with 600 TAXUS stents by means of percutaneous coronary intervention. The short and long term outcomes were compared between these 2 groups.
  
  
  RESULTS
  The success rate of stent implantation was 99.2% (606/611) and 98.8% (445/450) in the CYPHER stent and TAXUS stent groups respectfully. The overall rate of major cardiac events, including death, acute myocardial infarction (AMI) target lesion revascularization (TLR), and major adverse cardiac event (MACE), during hospitalization and 6 - 8 month' follow-up were 0.65% and 2.3% in the CYPHER stent group, not significantly different from those of the TAXUS stent group (1.3% and 3.2% respectively). The restenosis rate of the TAXUS stent group was 7.3%, a little higher than that of the CYPHER stent group (14%), but without significant difference.
  
  
  CONCLUSIONS
  CYPHER and TAXUS DES are both safe and effective in CHD patients with complicated lesions. There is an increasing tendency of restenosis rate in the TAXUS stent group in comparison with the CYPHER stent.
authors.affiliation: Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China.
authors.forename: Ji-lin
authors.initials: JL
authors.lastname: Chen
authors.forename: Run-lin
authors.initials: RL
authors.lastname: Gao
authors.forename: Yue-jin
authors.initials: YJ
authors.lastname: Yang
authors.forename: Shu-bin
authors.initials: SB
authors.lastname: Qiao
authors.forename: Xue-wen
authors.initials: XW
authors.lastname: Qin
authors.forename: Min
authors.initials: M
authors.lastname: Yao
authors.forename: Hai-bo
authors.initials: HB
authors.lastname: Liu
authors.forename: Bo
authors.initials: B
authors.lastname: Xu
authors.forename: Yong-jian
authors.initials: YJ
authors.lastname: Wu
authors.forename: Jin-qing
authors.initials: JQ
authors.lastname: Yuan
authors.forename: Jue
authors.initials: J
authors.lastname: Chen
authors.forename: Jun
authors.initials: J
authors.lastname: Dai
authors.forename: Shi-jie
authors.initials: SJ
authors.lastname: You
authors.forename: Wei-hua
authors.initials: WH
authors.lastname: Ma
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D003327:Coronary Disease / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D020123:Sirolimus